PEA15
适用: 人
ELISA, IHC (p), IF (cc), IF (p), IHC (fro)
宿主: 兔
Polyclonal
unconjugated
应用备注
ELISA: 1: 40000approx. 1: 60000. WB: 1: 500approx. 1: 1000. IHC: 1: 50approx. 1: 200. IF: 1: 50approx. 1: 200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
HMAT1 antibody, HUMMAT1H antibody, MAT1 antibody, MAT1H antibody, PEA-15 antibody, PED antibody, Pea15a antibody, PEA15 antibody, DKFZp459O1410 antibody, proliferation and apoptosis adaptor protein 15 antibody, phosphoprotein enriched in astrocytes 15 antibody, proliferation and apoptosis adaptor protein 15 L homeolog antibody, Astrocytic phosphoprotein PEA-15 antibody, PEA15 antibody, Pea15 antibody, pea15.L antibody, pea15 antibody
背景
PEA-15 (phosphoprotein enriched in astrocytes) exists in an non-phosphorylated form (N), and two phosphorylated forms, Pa and Pb. PEA-15 is an endogenous substrate for PKC, which mediates the transition from Pa to Pb. The level of PEA-15 phosphorylation changes upon depolymerization or stabilization of tubulins, indicating that PEA-15 co-localizes with microtubules. The first 80 amino acids of PEA-15 correspond to the death effector domain (DED), which is a domain found in proteins that regulate apoptotic signaling pathways. The DED domain is necessary for PEA-15 to block Ras suppression. Although PEA-15 is predominantly expressed in the central nervous system, low levels of PEA-15 are expressed in liver and kidney, and higher levels in muscle. PEA-15 is also referred to as PED, phosphoprotein enriched in diabetes, for its elevated expression in type 2 diabetic patients.Synonyms: Astrocytic phosphoprotein PEA-15, PED, Phosphoprotein enriched in diabetes